Late-Breaking Science at AAN 2025: Shaping the Future of Neurology
The 77th Annual Meeting of the American Academy of Neurology (AAN 2025), held from April 5–9 in San Diego and online, served as a pivotal forum for advancing research in neurology, with particular relevance to neurodegenerative diseases. As one of the largest gatherings of neurologists globally, the conference provided a critical platform for unveiling new data, fostering cross-disciplinary collaboration, and translating scientific discoveries into clinical strategies.
FDA Approves Simplera Sync™ Sensor for MiniMed™ 780G System; BVI Medical Secures FDA 510(k) Clearance for Leos™ Laser Endoscopy System in Ophthalmology; Surmodics Announces TRANSCEND Trial Data Supporting SurVeil™ Drug-Delivery Platform; Elutia Launches EluPro™ Registry Study to Gather Real-World Clinical Data; BD Launches Next-Generation AI-Driven Hemodynamic Monitoring and Industry-First Bioabsorbable Mesh for Umbilical Hernia Repair
Notizia - Recent Pharma, Healthcare and Biotech Happenings
Apr 24, 2025
Exploring the Impact of AI in Mental Health: How it is Going to Revolutionize Diagnosis and Treatment for a Better Tomorrow?
Articles
Apr 23, 2025
FDA Approves Sanofi/Regeneron’s DUPIXENT as First New CSU Therapy in Over a Decade; Gilead’s TRODELVY + KEYTRUDA Shows PFS Benefit in PD-L1+ TNBC; Tempest’s TPST-1495 Gets FDA Orphan Tag for FAP; uniQure’s AMT-130 Granted FDA Breakthrough for Huntington’s; NeuroNOS’ BA-102 Secures FDA Orphan Status for Phelan-McDermid Syndrome
Notizia - Recent Pharma, Healthcare and Biotech Happenings
Apr 22, 2025
ACC.25 Highlights: Groundbreaking Advances in Cardiovascular Medicine and Emerging Therapeutics
Articles
Apr 21, 2025
Groundbreaking Alzheimer’s Therapies: From Pipeline to Patient Care
Articles
Apr 18, 2025
Mar 24, 2025
An Insight Into the Weight Loss and Obesity Market
Mar 14, 2025
Obesity Treatment: Which Pipeline Therapy Will Revolutionize the Therapeutics Segment?
Mar 02, 2025
Long-Awaited Victory: Fabre-Kramer’s Major Depressive Disorder Treatment Drug Gains FDA Approval
Mar 02, 2025
Will a Robust Pipeline Address the Major Depressive Disorder Treatment Conundrum?
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Newsletter/Whitepaper
The therapy for aHUS is primarily supportive, focusing on managing acute kidney injury and systemic complications, with renal replacement therapy required for patients with uremia, fluid overload, or electrolyte abnormalities. Specific treatments include plasma exchange and complement inhibitors like eculizumab and ravulizumab, the only two approved drugs for aHUS treatment. In 2023, the total market size for aHUS in the United States was ~USD 900 million and is projected to surpass USD 1.5 billion by 2034, growing at a CAGR of 4.5% from 2020 to 2034. Among emerging therapies, PIASKY (crovalimab) and FABHALTA (iptacopan) are expected to significantly impact the market.
A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialisation presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their product. They wished to identify and evaluate the launch timelines, geographies of launch, First Launch company, commercial readiness, and salesforce of competitors.
A large pharma client was working to develop their cyclophosphamide API and FD and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors The client requested periodic reports (Quarterly) on the developmental milestones of competitor companies, thorough assessment of the competitor products through Secondary and Primary CI inputs.
A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.
A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.
A large client based in the USA, involved in drug delivery devices, with effective marketing and commercialisation presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products. They wished to identify and assess the technological competencies, clinical capabilities and commercial readiness of potential companies with a novel and non-invasive way of delivering drugs, which can include a variety of drugs/vaccines in their patch and successfully develop the product for commercial purposes, were of client’s interest.
A medium pharmaceutical client based in the United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.